US Stock MarketDetailed Quotes

TAK Takeda Pharmaceutical

Watchlist
  • 13.030
  • -0.040-0.31%
Close Apr 26 16:00 ET
  • 13.540
  • +0.510+3.91%
Post 19:56 ET
41.24BMarket Cap36.30P/E (TTM)

Takeda Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Takeda Pharmaceutical Earnings Date

Currency: JPY

Period

Q3 FY2024 Earnings

Feb 1, 2024

Revenue(YoY)

1.11T

+1.33%
EPS(YoY)

33.44

-11.84%
Analyst Rating

Buy

Mar 31, 2024

Takeda Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
Jul 31, 20242025/Q1-- / 1.038T--
May 9, 20242024/Q4-- / 899.902B--
Feb 1, 20242024/Q31.111T / 1.001T--
Oct 26, 20232024/Q21.043T / 990.336B--
Jul 27, 20232024/Q11.059T / 995.797B--
May 11, 20232023/Q4956.200B / 954.896B--
Feb 2, 20232023/Q31.097T / 996.345B--
Oct 27, 20222023/Q21.002T / 950.078B--
Jul 28, 20222023/Q1972.465B / 953.850B--
May 11, 20222022/Q4873.289B / 848.137B--
DatePeriodRevenue/EstimateEarnings Call
Jul 31, 20242025/Q1-- / 1.038T--
May 9, 20242024/Q4-- / 899.902B--
Feb 1, 20242024/Q31.111T / 1.001T--
Oct 26, 20232024/Q21.043T / 990.336B--
Jul 27, 20232024/Q11.059T / 995.797B--
May 11, 20232023/Q4956.200B / 954.896B--
Feb 2, 20232023/Q31.097T / 996.345B--
Oct 27, 20222023/Q21.002T / 950.078B--
Jul 28, 20222023/Q1972.465B / 953.850B--
May 11, 20222022/Q4873.289B / 848.137B--

Unlock Free Earnings Estimates

Takeda Pharmaceutical Earnings Reports

  • Takeda Pharmaceutical | 6-K: Quarterly Securities Report For The Nine-month Period and Three-month Quarter Ended December 31, 2023

    Feb 2 06:20 ET

  • Takeda Pharmaceutical | 6-K: Summary of Financial Statements for the Nine-month Period Ended December 31, 2023

    Feb 1 06:12 ET

  • Takeda Pharmaceutical | 6-K: Partial Amendment to Corporate Governance Report

    Dec 14, 2023 06:01 ET

  • Takeda Pharmaceutical | 6-K: The 147th (interim period) Business Report

    Nov 30, 2023 06:01 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Mar 31, 2024

    Buy

    • Buy

      33.33%

    • Hold

      66.67%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    %Chg